WO2000021507A3 - Pharmazeutisch wirksame zusammensetzung - Google Patents

Pharmazeutisch wirksame zusammensetzung Download PDF

Info

Publication number
WO2000021507A3
WO2000021507A3 PCT/CH1999/000482 CH9900482W WO0021507A3 WO 2000021507 A3 WO2000021507 A3 WO 2000021507A3 CH 9900482 W CH9900482 W CH 9900482W WO 0021507 A3 WO0021507 A3 WO 0021507A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically active
composition
active composition
gelatin capsules
tablets
Prior art date
Application number
PCT/CH1999/000482
Other languages
English (en)
French (fr)
Other versions
WO2000021507A2 (de
Inventor
Andreas Bockelmann
Original Assignee
Andreas Bockelmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andreas Bockelmann filed Critical Andreas Bockelmann
Priority to AU59653/99A priority Critical patent/AU5965399A/en
Publication of WO2000021507A2 publication Critical patent/WO2000021507A2/de
Publication of WO2000021507A3 publication Critical patent/WO2000021507A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmazeutisch wirksame Zusammensetzung, welche mindestens einen Thrombozytenaggregationshemmer aus der Gruppe der nicht-steroidalen Entzündungshemmer und mindestens ein antioxidativ wirkendes Polyphenol enthält, vorzugsweise in Form von Tabletten, Brausetabletten, Pulvern, vorzugsweise abgefüllt in Hartgelatinekapseln oder Weichgelatinekapseln, sowie Verwendung der Zusammensetzung für die vorbeugende Behandlung von okklusiven Gefässkrankheiten, vorzugsweise myokardialem Infarkt, Schlaganfall und Thrombosen.
PCT/CH1999/000482 1998-10-12 1999-10-11 Pharmazeutisch wirksame zusammensetzung WO2000021507A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59653/99A AU5965399A (en) 1998-10-12 1999-10-11 Pharmaceutically active composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH71598 1998-10-12
CH715/98 1998-10-12

Publications (2)

Publication Number Publication Date
WO2000021507A2 WO2000021507A2 (de) 2000-04-20
WO2000021507A3 true WO2000021507A3 (de) 2000-07-27

Family

ID=4193483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH1999/000482 WO2000021507A2 (de) 1998-10-12 1999-10-11 Pharmazeutisch wirksame zusammensetzung

Country Status (2)

Country Link
AU (1) AU5965399A (de)
WO (1) WO2000021507A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274842T3 (es) * 2001-08-18 2007-06-01 Cognis Ip Management Gmbh Mezclas de principios activos.
JP5335192B2 (ja) 2003-05-27 2013-11-06 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助食品組成物及びその使用
AU2006263430A1 (en) * 2005-06-29 2007-01-04 Mars, Incorporated Treatment of occlusive thrombosis
JP5179354B2 (ja) 2005-09-15 2013-04-10 大塚製薬株式会社 スーパーオキサイド抑制効果を有するプロブコールおよびテトラゾリルアルコキシ−ジヒドロカルボスチリル誘導体を含む併用薬
CH701576B1 (de) * 2007-04-20 2011-02-15 Andreas Bockelmann Wirkstoffkombination zur Prophylaxe von okklusiven Gefässkrankheiten und Krebs.
GB0819958D0 (en) * 2008-10-31 2008-12-10 Provexis Natural Products Ltd Therapeutic compositions
GB0819959D0 (en) 2008-10-31 2008-12-10 Provexis Natural Products Ltd Fruit extracts
US20100255088A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease
WO2011003223A1 (zh) * 2009-07-10 2011-01-13 杏辉天力（杭州）药业有限公司 治疗或预防心肌缺血引起的心绞痛或心肌梗塞的药物组合物
CN102321129B (zh) * 2011-07-14 2013-12-18 中国人民解放军第四军医大学 一种二苯乙烯苷注射剂及其制备工艺
EP2844083B1 (de) 2012-04-23 2018-07-25 University Of Oslo Verwendung von tomatenextrakt als blutdrucksenkendes mittel und verfahren zur herstellung von löslichem, zuckerfreiem tomatenextrakt
DE102012025005A1 (de) * 2012-12-20 2014-06-26 Herbalist & Doc Gesundheitsgesellschaft Mbh Verbesserte Thrombocytenaggregationshemmung mittels Kombination von NSAR und Veratrol oder dessen Analogen
GB201223365D0 (en) 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
JP7104032B2 (ja) 2016-11-02 2022-07-20 プロヴェクシス ナチュラル プロダクツ リミテッド 大気汚染の悪影響に対する水溶性トマト抽出物の保護

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340873A1 (de) * 1983-11-11 1985-05-23 ARTESAN GmbH Fabrik chemisch-pharmazeutischer Präparate, 3130 Lüchow Verwendung von magnesium-salicylat oder magnesium-acetylsalicylat
JPH02184262A (ja) * 1989-01-10 1990-07-18 Toko Inc スイッチングレギュレータ
RU2022557C1 (ru) * 1989-09-04 1994-11-15 Украинский научно-исследовательский институт терапии Способ лечения стенокардии
WO1998047534A1 (de) * 1997-04-18 1998-10-29 Klinge Pharma Gmbh Stabilisiertes arzneimittel enthaltend cysteinylderivate
WO2000007578A2 (de) * 1998-08-06 2000-02-17 Vascular Biotech Gmbh Wirkstoffkombination insbesondere zur prophylaxe und therapie von ischämischen organschäden und reperfusionssyndromen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340873A1 (de) * 1983-11-11 1985-05-23 ARTESAN GmbH Fabrik chemisch-pharmazeutischer Präparate, 3130 Lüchow Verwendung von magnesium-salicylat oder magnesium-acetylsalicylat
JPH02184262A (ja) * 1989-01-10 1990-07-18 Toko Inc スイッチングレギュレータ
RU2022557C1 (ru) * 1989-09-04 1994-11-15 Украинский научно-исследовательский институт терапии Способ лечения стенокардии
WO1998047534A1 (de) * 1997-04-18 1998-10-29 Klinge Pharma Gmbh Stabilisiertes arzneimittel enthaltend cysteinylderivate
WO2000007578A2 (de) * 1998-08-06 2000-02-17 Vascular Biotech Gmbh Wirkstoffkombination insbesondere zur prophylaxe und therapie von ischämischen organschäden und reperfusionssyndromen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199035, Derwent World Patents Index; AN 1990-264451, XP002134622, TSUTSUMISAKA H. ET AL.: "Blood platelet coagulation inhibiting agent" *
DATABASE WPI Week 199526, Derwent World Patents Index; AN 1995-198259, XP002134621, LADNYI A I; TSELUIKO V I; VOLKOV V I: "METHOD OF STENOCARDIA TREATMENT" *
J HLADOVEC: "Antithrombotic Effects of some Flavonoids Alone and Combined with Acetylsalicylic Acid", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH,DE,EDITIO CANTOR. AULENDORF, vol. 27(II), no. 10, 1 January 1977 (1977-01-01), pages 1989 - 1992, XP002082538, ISSN: 0004-4172 *
LUK'YANCHUK, V. D. ET AL: "Biochemoluminescent analysis of pharmacotherapeutic activity of acetylsalicylic acid in combination with quercetin in the hypoxic syndrome.", EKSPERIMENTAL'NAYA I KLINICHESKAYA FARMAKOLOGIYA, (1997) VOL. 60, NO. 1, PP. 62-64., XP002134620 *
ROTONDO S., ROTILIO D., CERLETTI C., DE GAETANO G.: "Red wine, aspirin and platelet function.", THROMBOSIS AND HAEMOSTASIS, vol. 76, no. 5, November 1996 (1996-11-01), pages 818 - 819, XP000892779 *
RYBACHENKO A I ET AL: "FLUORESCENT ANALYSIS OF THE DRUG QUERSALIN", FARMATSEVTYCHNYI ZHURNAL (KIEV) 1987, no. 6, 1987, pages 29 - 32, XP002134619, ISSN: 0367-3057 *

Also Published As

Publication number Publication date
AU5965399A (en) 2000-05-01
WO2000021507A2 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
WO2000021507A3 (de) Pharmazeutisch wirksame zusammensetzung
HUP9802448A2 (hu) Vérlemezke-aggregáció inhibitorvegyületei, ezek előállítása és alkalmazása és gyógyászati készítmények
HUP0301344A3 (en) Non-steroidal inflammation inhibitors, process for their preparation and pharmaceutical compositions containing them
CA2397447A1 (en) Reduced form of coenzyme q in high bioavailability stable dosage forms and related applications
HUP0300148A3 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
EP1734041A3 (de) Platelet adp rezeptor inhibitoren
CA2174338A1 (en) Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
NZ235337A (en) Pharmaceutical composition containing anticoagulant (e.g. warfarin) and a platelet inhibitory agent for treating/preventing myocardial infarction and stroke
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
MY125150A (en) Factor vlla inhibitors
HK1056118A1 (en) Medicinal compositions containing aspirin
EP1550448A4 (de) Histamin-freisetzungshemmer
HUP0203813A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use
WO2002000258A8 (fr) Compositions medicales de therapie angiogenique
CA2261040A1 (en) Pharmaceutical composition comprising combination useful for treatment or prevention of arteriosclerosis or xanthoma
CA2299420A1 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
EP1167354A3 (de) Racemisches Huperzin A
HUP0303006A3 (en) Retinoids for the treatment of emphysema, process for their preparation and pharmaceutical compositions containing them
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2003053394A3 (de) Verwendungen von apfelkernextrakten in kosmetischen oder pharmazeutischen zusammensetzungen
AU2208401A (en) Inhibitors of complement activation, their preparation and use
IL143987A (en) Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase